Drug to slow Alzheimer's well tolerated outside of clinical trial setting

Washington University in St. Louis

May 13, 2025

The Food and Drug Administration's approval in 2023 of lecanemab - a novel Alzheimer's therapy shown in clinical trials to modestly slow disease progression - was met with enthusia…